Publications matter when assessing the capabilities of bio-reagents. I would like to share several that prove the utility of these cells: David L. Simpson, Nolan L. Boyd, Sunjay Kaushal, Steve L. Stice, Samuel C. Dudley Jr. Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair. Biotechnology and Bioengineering Volume 109, Issue 1, pages 274–283, January 2012. DOI: 10.1002/bit.23301
Nolan L. Boyd, Ph.D., Kelly R. Robbins, Ph.D., Sujoy K. Dhara, D.V.M., Ph.D., Franklin D. West, Ph.D., and Steven L. Stice, Ph.D. Human Embryonic Stem Cell–Derived Mesoderm-like Epithelium Transitions to Mesenchymal Progenitor Cells. Tissue Eng Part A. 2009 August; 15(8): 1897–1907. Published online 2009 January 15. doi: 10.1089/ten.tea.2008.0351.
Images: (A) Phase contrast image of hMPro™ mesenchymal progenitor cells in culture. (B) Confocal image of hMPro™ cells stained for the early smooth muscle marker (αSMA;green), F-actin (red) and nuclei (blue). Exposure to 10ng/mL of transforming growth factor beta 1 (TGF-β1) for 12 days induces expression of alpha smooth muscle actin (αSMA) in WA09-derived mesenchymal progenitor cells, suggesting their ability to differentiate along the smooth muscle lineage.
These cells have the ability to:•Form adherent monolayers – ideal for 96- and 384-well formats for high throughput and high content cell-based assays.
•Differentiate into a wide variety of mesenchymal subtypes, including osteogenic and chondrogenic lineages (but not adipogenic)– ideal for drug discovery for a wide variety of biological targets and basic research in bone, cartilage, metabolic and immunological diseases.
•Passage up to 10X.
I will keep you posted on new applications.